Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01347736|
Recruitment Status : Active, not recruiting
First Posted : May 4, 2011
Last Update Posted : February 6, 2018
|Condition or disease||Intervention/treatment|
|Dermatologic Complications Pain Viral Infection||Other: scrambler therapy Other: questionnaire administration Procedure: dermatologic complications management/prevention|
I. To explore whether we can decrease post-herpetic neuralgia (PHN) pain with scrambler therapy.
OUTLINE: Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity. After the completion of study treatment, patients are followed up for 10 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Scrambler Therapy for the Treatment of Chronic Zoster Pain|
|Actual Study Start Date :||March 2011|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||September 2018|
Experimental: Treatment (pain therapy)
Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
Other: scrambler therapy
Undergo scrambler therapyOther: questionnaire administration
Ancillary studiesProcedure: dermatologic complications management/prevention
Undergo scrambler therapy
- Change in pain on a 0-10 numerical rating scale. [ Time Frame: 10 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01347736
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Charles Loprinzi||Mayo Clinic|